STEALTH BIOTHERAPEUTICS CORP | |||||
Condensed Consolidated Balance Sheets | |||||
(in thousands) | |||||
(unaudited) | |||||
June 30, | December 31, | ||||
2019 | 2018 | ||||
Assets | |||||
Current assets: | |||||
Cash and cash equivalents | $ 53,200 | $ 10,855 | |||
Prepaid expenses and other current assets | 1,408 | 2,438 | |||
Total current assets | 54,608 | 13,293 | |||
Property and equipment, net | 437 | 499 | |||
Deferred offering costs | - | 1,325 | |||
Other non-current assets | 250 | 406 | |||
Total assets | $ 55,295 | $ 15,523 | |||
Liabilities, convertible preferred shares and shareholders' equity (deficit) | |||||
Current liabilities: | |||||
Accounts payable | $ 8,970 | $ 11,023 | |||
Accrued expenses and other current liabilities | 9,264 | 13,826 | |||
Accrued interest payable | 1,013 | 7,297 | |||
Current portion of long-term debt | 6,437 | 8,465 | |||
Total current liabilities | 25,684 | 40,611 | |||
Long-term debt, less current portion | 10,326 | 10,317 | |||
Convertible notes payable | — | 103,257 | |||
Derivative liability | — | 36,567 | |||
Warrant liability | — | 100 | |||
Total liabilities | 36,010 | 190,852 | |||
Series A convertible preferred shares | — | 211,377 | |||
Total shareholders' equity (deficit) | 19,285 | (386,706) | |||
Total liabilities, convertible preferred shares and shareholders' equity (deficit) | $ 55,295 | $ 15,523 | |||
